NOVANTRONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVANTRONE (NOVANTRONE).
Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.
| Metabolism | Mitoxantrone is extensively metabolized in the liver via oxidation and conjugation, primarily by cytochrome P450 enzymes, forming inactive metabolites. Elimination is mainly via the hepatobiliary system with fecal excretion; small amounts are excreted renally. |
| Excretion | Primarily hepatic (biliary/fecal) elimination: ~25% as unchanged drug and metabolites in feces over 5 days; renal excretion accounts for ~11% (6-11%) as unchanged drug. Less than 10% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life: 23-215 hours (mean ~37 hours). The long half-life reflects extensive tissue distribution and slow elimination, allowing weekly dosing. |
| Protein binding | ~78% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Mean Vd: 8-22 L/kg (range 6-44 L/kg). Large Vd indicates extensive tissue distribution and binding to intracellular components. |
| Bioavailability | Intravenous: 100% (only route of administration). Oral bioavailability is <5% and not clinically relevant; no other routes used. |
| Onset of Action | Intravenous: Clinical effects (e.g., reduction in white blood cell count) observed within 1-2 weeks after a single dose. |
| Duration of Action | Myelosuppressive effects (leukopenia, thrombocytopenia) persist for 2-3 weeks; cardiac toxicity may become evident months to years after treatment. |
12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR >50 mL/min. For GFR 10-50 mL/min: administer 75% of normal dose. For GFR <10 mL/min: administer 50% of normal dose. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25%. Child-Pugh Class C: reduce dose by 50%. |
| Pediatric use | Safety and efficacy not established; not recommended for pediatric use. |
| Geriatric use | Monitor cardiac function closely due to increased risk of cardiotoxicity. Higher risk of myelosuppression; consider lower initial doses based on renal function (see renal adjustment). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOVANTRONE (NOVANTRONE).
| Breastfeeding | Mitoxantrone is excreted into human breast milk; the milk-to-plasma ratio is not well characterized. Due to the potential for serious adverse reactions in nursing infants, including immunosuppression and cardiotoxicity, breastfeeding is contraindicated during therapy and for at least 1 month after the last dose. |
| Teratogenic Risk | Mitoxantrone is teratogenic in animals and is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of spontaneous abortion and major congenital malformations. Second and third trimester exposure may cause fetal growth restriction, myelosuppression, and cardiac toxicity. Use during pregnancy is contraindicated unless the potential benefit outweighs the risk. |
■ FDA Black Box Warning
1. Mitoxantrone should be administered under the supervision of a physician experienced in the use of cancer chemotherapy agents. 2. Cardiac toxicity, including congestive heart failure, can occur and may be cumulative; risk increases with prior anthracycline use, mediastinal radiotherapy, pre-existing cardiac disease, or concomitant cardiotoxic drugs. 3. Secondary acute myeloid leukemia (AML) has been reported in patients treated with mitoxantrone-containing regimens. 4. Severe myelosuppression will occur.
| Serious Effects |
["Hypersensitivity to mitoxantrone or any component of the formulation","Significant pre-existing bone marrow suppression (e.g., baseline neutrophil count <1500/mm³, platelet count <50,000/mm³)","Patients with clinically significant cardiac disease (e.g., myocardial infarction within 6 months, unstable angina, severe heart failure)"]
| Precautions | ["Cardiotoxicity: Monitor left ventricular ejection fraction (LVEF) before and during therapy; cumulative dose limit of 140 mg/m² in multiple sclerosis patients.","Myelosuppression: Severe neutropenia, thrombocytopenia, and anemia; monitor complete blood counts regularly.","Secondary malignancies: Increased risk of AML and myelodysplastic syndrome.","Hepatic impairment: Dose reduction may be necessary; monitor liver function.","Renal impairment: Use with caution; adjust dose if severe.","Immunosuppression: Increased risk of infections; avoid live vaccines.","Pregnancy: Can cause fetal harm; advise effective contraception.","Extravasation: Can cause tissue necrosis; administer via IV with care."] |
Loading safety data…
| Fetal Monitoring | Maternal: Complete blood count with differential, cardiac function (left ventricular ejection fraction) at baseline and periodically, liver function tests, and serum uric acid. Fetal: Serial ultrasound for growth and anatomy if exposure occurs during pregnancy, and neonatal cardiac evaluation if exposed in utero. |
| Fertility Effects | Mitoxantrone may cause gonadal suppression and irreversible amenorrhea in premenopausal women, leading to premature ovarian failure and reduced fertility. Men may experience oligospermia or azoospermia. Effects on fertility are dose- and duration-dependent. |